Italy’s decision to extend from 21 to 42 days the time window for the administration of anti-Covid vaccines to mrna, such as pfizer or modern preparations, is generating several diverbs between pharmaceutical manufacturers and Italian health authorities. A recommendation that has created confusion, colliding with those that are the indications for the Italian vaccination campaign. “As a doctor, I answer very clearly: the interval between the first and the second administration of the prolonged vaccine at 42 days does not affect the effectiveness of immunization, and allows us to manage to administer many more doses of vaccine”.
As a result, “affirmations such as those we heard yesterday (from pfizer) risk only creating disconcerting and I think they would be hopefully avoidable”. According to the president of the css and cts it is possible to “prolong, as far as possible, the interval between the two administrations without going to inficiare effectiveness”. Translated: “42 days away for vaccines at mrna and 12 weeks for vaccines with adenoviral vector (AstraZeneca)”.
Pfizer: ‘Recommendations on alternative dosing schemes are the responsibility of health authorities’pfizer, in a note, specified: “For our company, the vaccination plan is not questioned, the company is limited to reporting what emerged from the record studies”. ‘Recommendations on alternative dosing regimes’, the company explains, are in fact ‘the responsibility of health authorities and may include recommendations from public health principles’. Closed doors from the American company to Italy?
Pfizer repeats: “We remain committed to our ongoing dialogue with health authorities and governments, and in our ongoing efforts to share data to help inform any public health decision to defeat this devastating pandemic.”